CN108014236A - A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application - Google Patents
A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application Download PDFInfo
- Publication number
- CN108014236A CN108014236A CN201711331229.3A CN201711331229A CN108014236A CN 108014236 A CN108014236 A CN 108014236A CN 201711331229 A CN201711331229 A CN 201711331229A CN 108014236 A CN108014236 A CN 108014236A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- pharmaceutical composition
- pharmaceutical chemicals
- bulk pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
- A61K36/126—Drynaria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition, belong to tcm field.The pharmaceutical composition is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：15~60 parts of frankincense, 20~65 parts of myrrh, 10~55 parts of dragon's blood, 15~50 parts of the bark of eucommia, 5~40 parts of teasel root, 5~45 parts of ramulus mori, 20~50 parts of radix cyathulae, 15~40 parts of the rhizome of davallia, 25~55 parts of ground bettle, 5~30 parts of Chinese ephedra, 3~20 parts of native copper.Present invention also offers the preparation method and purposes of the pharmaceutical composition.Clinical test proves that pharmaceutical composition compatibility of the present invention is precise and appropriate, and each flavour of a drug complement each other, and have no toxic side effect, and can effectively treat the healing after bone split or the reduction of the fracture, has stronger actual application value.
Description
Technical field
The invention belongs to tcm field, and in particular to a kind of to treat bone split or the pharmaceutical composition of fracture and its preparation side
Method and purposes.
Background technology
Fracture means a kind of disease with causing bone parts or being fully broken due to reasons such as wound or pathology.Bone split
Medically it is known as fissure fracture, belongs to one kind in classification of fracture.Children and the elderly are more common in, the young and the middle aged also happens occasionally.
Patient often fractures for a position, and minority is multiple fracture.It can recover original work(through appropriate processing, most patients in time
Can, a few patients can leave different degrees of sequelae.Patient need to generally lie in bed 2-3 months during fractures, to patient's
Life is made troubles.Either curative effect is difficult as people's will either has certain side effect or the cost higher for existing various medicines.
Now have no frankincense, myrrh, dragon's blood, the bark of eucommia, teasel root, ramulus mori, radix cyathulae, the rhizome of davallia, ground bettle, Chinese ephedra and nature
Report of the copper cooperation for the healing after treating bone split or the reduction of the fracture.
The content of the invention
The present invention provides a kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application.
Present invention firstly provides a kind of pharmaceutical composition, it is that the bulk pharmaceutical chemicals containing following weight proportioning are prepared
's：
15~60 parts of frankincense, 20~65 parts of myrrh, 10~55 parts of dragon's blood, 15~50 parts of the bark of eucommia, 5~40 parts of teasel root, ramulus mori 5
~45 parts, 20~50 parts of radix cyathulae, 15~40 parts of the rhizome of davallia, 25~55 parts of ground bettle, 5~30 parts of Chinese ephedra, native copper 3~20
Part.
Further, it is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportioning：
15~60 parts of frankincense, 20~65 parts of myrrh, 10~55 parts of dragon's blood, 15~50 parts of the bark of eucommia, 5~40 parts of teasel root, ramulus mori 5
~45 parts, 20~50 parts of radix cyathulae, 15~40 parts of the rhizome of davallia, 25~55 parts of ground bettle, 5~30 parts of Chinese ephedra, native copper 3~20
Part.
Preferably, it is the preparation being prepared by the raw material of following weight proportion：
35~50 parts of frankincense, 30~45 parts of myrrh, 10~30 parts of dragon's blood, 15~35 parts of the bark of eucommia, 10~35 parts of teasel root, ramulus mori
20~40 parts, 25~45 parts of radix cyathulae, 30~40 parts of the rhizome of davallia, 20~35 parts of ground bettle, 5~20 parts of Chinese ephedra, native copper 3~15
Part.
It is highly preferred that it is the preparation being prepared by the raw material of following weight proportion：
40 parts of frankincense, 40 parts of myrrh, 30 parts of dragon's blood, 30 parts of the bark of eucommia, 30 parts of teasel root, 30 parts of ramulus mori, 30 parts of radix cyathulae, bone are broken
30 parts of benefit, 30 parts of ground bettle, 15 parts of Chinese ephedra, 15 parts of native copper.
Foregoing is with frankincense, myrrh, dragon's blood, the bark of eucommia, teasel root, ramulus mori, radix cyathulae, the rhizome of davallia, ground bettle, Chinese ephedra
With the medicinal powder of native copper, either water or extractive with organic solvent are active ingredient plus acceptable auxiliary material or auxiliary in pharmacy
The preparation that helping property component is prepared.
" pharmaceutically acceptable auxiliary material " of the present invention, refers to the material being included in addition to the active ingredient (s in formulation,
Include but are not limited to filler (diluent), lubricant (glidant or antitack agent), dispersant, wetting agent, adhesive, tune
Save agent, solubilizer, antioxidant, bacteriostatic agent, emulsifying agent, disintegrant etc..Adhesive includes syrup, Arabic gum, gelatin, sorb
(such as microcrystalline cellulose, sodium carboxymethylcellulose, ethyl cellulose or hydroxypropyl are fine for alcohol, tragacanth, cellulose and its derivates
Tie up element etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.；Filler include lactose, Icing Sugar, dextrin, starch and
Its derivative, cellulose and its derivates, inorganic calcium salt (such as calcium sulfate, calcium phosphate, calcium monohydrogen phosphate, precipitated calcium carbonate), mountain
Pears alcohol or glycine etc.；Lubricant includes superfine silica gel powder, magnesium stearate, talcum powder, aluminium hydroxide, boric acid, hydrogenated vegetable oil, poly-
Ethylene glycol etc.；Disintegrant includes starch and its derivative (such as sodium carboxymethyl starch, Explotab, pregelatinized starch, improvement
Starch, hydroxypropul starch, cornstarch etc.), polyvinylpyrrolidone or microcrystalline cellulose etc.；Wetting agent includes dodecyl sulphur
Sour sodium, water or alcohol etc.；Antioxidant packages are containing sodium sulfite, sodium hydrogensulfite, sodium pyrosulfite, dibutyl benzoic acid etc.；Bacteriostatic agent bag
Containing 0.5% phenol, 0.3% cresols, 0.5% anesin etc.；Conditioning agent includes hydrochloric acid, citric acid, potassium hydroxide (sodium), Chinese holly
Rafter acid sodium and buffer (including sodium dihydrogen phosphate and disodium hydrogen phosphate) etc.；Emulsifying agent includes Tween-80, aliphatic acid sorb
Smooth, pluronic gram F-68, lecithin, Fabaceous Lecithin etc.；Solubilizer includes Tween-80, bile, glycerine etc..
The pharmaceutically acceptable complementary component, it has certain physiological activity, but the addition of the component will not change
Become the leading position of above-claimed cpd or derivative in treatment of diseases, and only play auxiliary effect, these auxiliary work(
Effect is only the utilization to the component known activity, is the usual adjuvant treatment modality of field of medicaments.If by it is above-mentioned it is complementary into
Divide and be used cooperatively with the compounds of this invention, still should belong to the scope of protection of the invention.
Wherein, the preparation is oral formulations.
Wherein, the preparation is powder, decoction, granule, tablet, capsule, oral liquid or pill.
Present invention also offers the preparation method of aforementioned pharmaceutical compositions, it is comprised the steps of：
1) each raw material is weighed by weight ratio；
2) bulk pharmaceutical chemicals directly beat powder, or bulk pharmaceutical chemicals are added water to cook or organic solvent extracts, extracting solution concentration, along with medicine
Acceptable auxiliary material or complementary component are prepared into preparation in.
Water extract is used as medicine with medicinal powder, is Chinese medicine tradition occupation mode, after water carries, since the soluble end of water is wide, and energy
Enough by most of active ingredient dissolution, make medicine be easier to be absorbed by the body, work faster, such as the form of medication such as decoction；With
Original powder is used as medicine, and the surface area of medicinal powder is larger, is also beneficial to the absorption of active ingredient in vivo in medicinal material, but medicinal material is un-extracted,
Active ingredient still needs to the re-absorption of dissolution in vivo, its opposite water extract that works is slower, but also weakens and be harmful into medicinal material at the same time
Divide the toxicity caused by human body, be suitable for long-term use, original powder is such as prepared into pill form of medication.At present in pharmacy
During, ethanol extracts medicine as solvent, and one of most commonly seen extracting mode, and ethanol is molten for semi-polarity
Agent, solubility property circle can dissolve water miscible some components between polarity and nonpolar solvent, can also dissolve nonpolar molten
Some components of agent dissolving, usually replace decocting with ethanol extraction, so as to avoid the dissolution of a large amount of invalid components, raising effectively into
The concentration and extraction efficiency divided, but the price of ethanol is expensive compared with water, in the big production of modern pharmaceutical industry, is produced into save
This, usually or based on decocting.In the case where the water extract of known compositions of the present invention has physiological activity, in order to adapt to
Various productions and demand when using, can optionally water carries, original powder, alcohol extracting or combinations thereof method prepare specific agent
Type.
Wherein, specific preparation method is as follows：
Powder：Weigh bulk pharmaceutical chemicals, beat powder, sieve, to obtain the final product；
Decoction：Bulk pharmaceutical chemicals are weighed, are decocted, filtering, to obtain the final product；
Granule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate concentration, dry, addition auxiliary material or auxiliary
Helping property component, mixes, granulation, whole grain, drying, to obtain the final product；
Tablet：Bulk pharmaceutical chemicals are weighed, beat powder, direct powder compression, to obtain the final product；
Capsule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate is concentrated and dried, and adds auxiliary material or auxiliary
Property component, mix, it is encapsulated, to obtain the final product；
The water-bindered pill：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add excipient, water pill is dry, to obtain the final product；
Honeyed bolus：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add honey, pill is dry, to obtain the final product；
Dripping pill：Bulk pharmaceutical chemicals are weighed, adds water or organic solvent to extract, filters, matrix is added in filtrate, mix heating and melting,
Instill in not miscible condensate liquid and condense, to obtain the final product.
The organic solvent is the ethanol of various concentrations, such as the ethanol of 25%-95%.
Present invention also offers purposes of the aforementioned pharmaceutical compositions in treatment bone split or fracture medicine is prepared.
Qi and blood is the material base of physical activity.《Plain Questions menstruation regulating opinion》Say：" owner of people, blood and gas ear ".《Hardly possible is through
22 is difficult》Say：" qi warming body, blood nourishing." gas has warm use, blood, which has, moistens foster function, four limbs bones of the body collectively, the five internal organs six
Internal organs, all relies qi and blood foster to moisten.Bone is the important component of human body.Certainly also it be unable to do without supplementing nutrition for qi and blood.《Ling Shu Miraculous Pivot or Divine Axis passages through which vital energy circulates
》Say：" part of the body cavity above the diaphragm housing the heart and lungs outlet, the nourishing the bone section with warm boundary between muscles ".《This Tibetan of Ling Shu Miraculous Pivot or Divine Axis piece》Add：" passages through which vital energy circulates person, thus qi and blood circulation promotion and it is flourish cloudy
Sun, moistens muscles and bones, sharp joint person ".It is the important substance of bone of supplementing nutrition to illustrate qi and blood.Passages through which vital energy circulates is unimpeded, and qi and blood reconciles, and bone is just
It can obtain and supplement nutrition and make powerful muscle and bone.Accordingly it is considered that：After fracture, it is necessary to which passages through which vital energy circulates is unimpeded, and qi and blood, which reconciles, to heal.If
Qi depression to blood stasis, passages through which vital energy circulates occlusion, then derangement of Qi and blood, the broken ends of fractured bone cannot nourish, and just be difficult to heal.《General Records of Holy Universal Relief traumatics fracture door》Cloud：
" people all over the body, defend by blood Ying Qi, and circulation is infinite, or muscles joint, causes to be traumaticd fracture by mistake, then qi and blood stasis pain, must not hinder,
Must not roll over and continue "." arteries and veins person's house of blood, in blood arteries and veins, passes through and is managed in meat, ring Zhou Yishen, because solid outside its human body, lead in passages through which vital energy circulates, is energy
It is normal that streamer does not lose its.If because traumatiing fracture, interior dynamic channels and collaterals, the road of blood, must not declare it is logical, siltation do not dissipate, for swell be pain, control and preferably remove evil
Become silted up, make qi and blood circulation, then can answer.Chen Shiduo《The dialectical record of all kinds of diseases and ailments》Say：" blood not become silted up and do not go by reviver, and silt does not go then that bone cannot
Connect.”
Qi and blood is the important substance of bone of supplementing nutrition.After fracture, as qi and blood is vigorous, with regard to broken ends of fractured bone connection can be accelerated；Instead
It, such as insufficiency of vital energy and blood, fractures with regard to refractory conjunction.
《Plain Questions declares a five gas pieces》Say：" Shen controls bone "；《The big opinion of YIN YANG classification of natural phenomena》Say：" kidney producing bone marrow "；《Six sections are hidden as opinion》
Also say：" kidney person,, it is filled in bone ".The vital essence of kidney is prompted, bone can be given birth to and brought up.The vigorous then bone growth of kidney qi, kidney qi decline
Then bone also fails therewith.
The strong main body sclerotin of pharmaceutical composition of the present invention, and just because of this so that fracture or bone split are better and are
To rehabilitation.
In pharmaceutical composition of the present invention, frankincense, myrrh are monarch drug in a prescription, analgesic therapy of invigorating blood circulation, scattered stasis pain, detumescence and promoting granulation；Dragon's blood, Du
Secondary is ministerial drug, removing blood stasis and hemostasis, myogenic sore, inducing diuresis for removing edema；Assistant is with teasel root, the rhizome of davallia, ground bettle, native copper, The strong bone of kidney tonifying, change
The stasis of blood relieves pain, and with radix cyathulae, ramulus mori priming power downlink, using Chinese ephedra to make, helps the efficacy of a drug to play by means of the power of its a surname's hair.
Pharmaceutical composition of the present invention can be obviously improved the situation after bone split or the reduction of the fracture, patient is healed, nontoxic secondary work
With having stronger actual application value.
Obviously, the above according to the present invention, according to the ordinary technical knowledge and customary means of this area, is not departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The embodiment of form by the following examples, remakes further specifically the above of the present invention
It is bright.But the scope that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to following example.It is all to be based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Embodiment
The preparation of embodiment 1, medicinal tablet of the present invention
Take frankincense 40g, myrrh 40g, dragon's blood 30g, bark of eucommia 30g, teasel root 30g, ramulus mori 30g, radix cyathulae 30g, the rhizome of davallia
30g, ground bettle 30g, Chinese ephedra 15g, native copper 15g, beat powder, direct powder compression, up to tablet.
The preparation of embodiment 2, medicine decoction of the present invention
Take frankincense 15g, myrrh 65g, dragon's blood 10g, bark of eucommia 50g, teasel root 5g, ramulus mori 45g, radix cyathulae 20g, rhizome of davallia 40g,
Ground bettle 25g, Chinese ephedra 5g, native copper 20g, soak decoction, merging filtrate, filtering, up to decoction.
The preparation of embodiment 3, medicine capsule of the present invention
Take frankincense 60g, myrrh 20g, dragon's blood 55g, bark of eucommia 15g, teasel root 40g, ramulus mori 5g, radix cyathulae 50g, rhizome of davallia 15g,
Ground bettle 55g, Chinese ephedra 30g, native copper 3g, add water to cook extraction, are condensed into medicinal extract, add auxiliary material, mix, packing, up to glue
Wafer.
The preparation of embodiment 4, the medicine water-bindered pill of the present invention
Frankincense 35g, myrrh 45g, dragon's blood 10g, bark of eucommia 35g, teasel root 35g, ramulus mori 20g, radix cyathulae 25g, rhizome of davallia 40g,
Ground bettle 20g, Chinese ephedra 20g, native copper 3g, beat powder, sieving, add excipient, water pill is dry, up to the water-bindered pill.
The preparation of embodiment 5, medicine honeyed bolus of the present invention
Frankincense 50g, myrrh 30g, dragon's blood 30g, bark of eucommia 15g, teasel root 10g, ramulus mori 40g, radix cyathulae 45g, rhizome of davallia 30g,
Ground bettle 35g, Chinese ephedra 5g, native copper 15g, beat powder, sieving, add honey, pill is dry, up to honeyed bolus.
The preparation of embodiment 6, medicinal tablet of the present invention
Frankincense 37g, myrrh 42g, dragon's blood 32g, bark of eucommia 33g, teasel root 23g, ramulus mori 25g, radix cyathulae 40g, rhizome of davallia 27g,
Ground bettle 40g, Chinese ephedra 17g, native copper 11g, are extracted with ethanol, obtain ethanol extract, are condensed into medicinal extract, add starch system
Grain, whole grain, tabletting, up to tablet.
The preparation of embodiment 7, medicinal tablet of the present invention
Frankincense 42g, myrrh 37g, dragon's blood 20g, bark of eucommia 25g, teasel root 22g, ramulus mori 30g, radix cyathulae 35g, rhizome of davallia 35g,
Ground bettle 27g, Chinese ephedra 12g, native copper 9g, beat powder, direct powder compression, up to tablet.
The preparation of embodiment 8, medicine oral liquid of the present invention
Frankincense 40g, myrrh 35g, dragon's blood 30g, bark of eucommia 27g, teasel root 25g, ramulus mori 15g, radix cyathulae 35g, rhizome of davallia 17g,
Ground bettle 45g, Chinese ephedra 25g, native copper 12g, soak decoction, merging filtrate, concentration, embedding, sterilizing, up to oral liquid.
Beneficial effects of the present invention are proved below by way of test example：
Clinical efficacy after the medicine composite for curing bone split of the present invention of test example 1 or the reduction of the fracture
1 experiment material
1.1 experimental drug
Pharmaceutical composition of the present invention, is prepared by embodiment 1.
1.2 patient data
Case totally 35 is observed, the age is 42 years old average.
2 experimental methods
2.1 include case standard
Through《Doctor trained in Western medicine Illnesses Diagnoses criterion of therapeutical effect》, the patient that is 1. diagnosed as fracture.2. it is diagnosed as the patient of bone split.
2.2 Excluded cases standards
1. pregnant woman, those who are allergic to this drug.
2. it is associated with the severe primary disease such as angiocarpy, liver, kidney and hemopoietic system, mental patient.
3. all do not meet inclusive criteria, not by regulation medication, it can not judge that curative effect or data be not congruent and affect the treatment or pacify
Full property judgement person.
2.3 curative effects judge
Cure：Joint structure is normal, and symptom disappears, and function is wholly or substantially recovered.
Improve：Joint structure is normal, and symptom improves, and funtion part is limited.
It is not cured：Dislocation does not reset, and symptom is without improvement, dysfunction.
2.4 medication
This medicine daily 3 times, it is early, middle and late respectively to take once, it need to be taken with yellow rice wine or red wine, to help the efficacy of a drug, each taking
Equivalent to 3 grams crude drugs of the weight of medicine, take 1 month.
3 experimental results
| Cure (example) | Improve (example) | It is not cured (example) | Total effective rate | |
| Treatment group | 35 | 0 | 0 | 100% |
The experiment results show that patient takes 1 month visible positive effect of pharmaceutical composition of the present invention, total effective rate 100%,
Pharmaceutical composition of the present invention can effectively improve the situation after bone split or the reduction of the fracture.
To sum up, the strong main body sclerotin of pharmaceutical composition of the present invention, the situation that can be obviously improved after bone split or the reduction of the fracture,
Patient is healed, mitigate patient suffering, have no toxic side effect, there is stronger actual application value.
Claims (10)
- A kind of 1. pharmaceutical composition, it is characterised in that：It is that the bulk pharmaceutical chemicals containing following weight proportioning are prepared：15~60 parts of frankincense, 20~65 parts of myrrh, 10~55 parts of dragon's blood, 15~50 parts of the bark of eucommia, 5~40 parts of teasel root, ramulus mori 5~45 Part, 20~50 parts of radix cyathulae, 15~40 parts of the rhizome of davallia, 25~55 parts of ground bettle, 5~30 parts of Chinese ephedra, 3~20 parts of native copper.
- 2. pharmaceutical composition according to claim 1, it is characterised in that：It is prepared by the bulk pharmaceutical chemicals of following weight proportioning The preparation formed：15~60 parts of frankincense, 20~65 parts of myrrh, 10~55 parts of dragon's blood, 15~50 parts of the bark of eucommia, 5~40 parts of teasel root, ramulus mori 5~45 Part, 20~50 parts of radix cyathulae, 15~40 parts of the rhizome of davallia, 25~55 parts of ground bettle, 5~30 parts of Chinese ephedra, 3~20 parts of native copper.
- 3. pharmaceutical composition according to claim 2, it is characterised in that：It is by following weight proportion raw material prepare and Into preparation：35~50 parts of frankincense, 30~45 parts of myrrh, 10~30 parts of dragon's blood, 15~35 parts of the bark of eucommia, 10~35 parts of teasel root, ramulus mori 20~ 40 parts, 25~45 parts of radix cyathulae, 30~40 parts of the rhizome of davallia, 20~35 parts of ground bettle, 5~20 parts of Chinese ephedra, 3~15 parts of native copper.
- 4. pharmaceutical composition according to claim 3, it is characterised in that：It is by following weight proportion raw material prepare and Into preparation：40 parts of frankincense, 40 parts of myrrh, 30 parts of dragon's blood, 30 parts of the bark of eucommia, 30 parts of teasel root, 30 parts of ramulus mori, 30 parts of radix cyathulae, the rhizome of davallia 30 Part, 30 parts of ground bettle, 15 parts of Chinese ephedra, 15 parts of native copper.
- 5. according to Claims 1 to 4 any one of them pharmaceutical composition, it is characterised in that：It is medicinal powder by bulk pharmaceutical chemicals, original The water or extractive with organic solvent for expecting medicine are active ingredient, plus acceptable auxiliary material in pharmacy or the preparation of complementary component Into preparation.
- 6. pharmaceutical composition according to claim 5, it is characterised in that：The preparation is oral formulations.
- 7. pharmaceutical composition according to claim 6, it is characterised in that：The preparation is powder, decoction, granule, piece Agent, capsule, oral liquid or pill.
- 8. the preparation method of claim 1~7 any one of them pharmaceutical composition, it is characterised in that：It is comprised the steps of：1) each raw material is weighed by weight ratio；2) bulk pharmaceutical chemicals directly beat powder, or bulk pharmaceutical chemicals are added water to cook or organic solvent extracts, extracting solution concentration, along with pharmacy Acceptable auxiliary material or complementary component are prepared into preparation.
- 9. preparation method according to claim 8, it is characterised in that：The preparation method is as follows：Powder：Weigh bulk pharmaceutical chemicals, beat powder, sieve, to obtain the final product；Decoction：Bulk pharmaceutical chemicals are weighed, are decocted, filtering, to obtain the final product；Granule：Bulk pharmaceutical chemicals are weighed, add water or organic solvent to extract, filtering, filtrate concentration, dry, addition auxiliary material or complementary Component, mixes, granulation, whole grain, drying, to obtain the final product；Tablet：Bulk pharmaceutical chemicals are weighed, beat powder, direct powder compression, to obtain the final product；Capsule：Weigh bulk pharmaceutical chemicals, add water or organic solvent to extract, filtering, filtrate is concentrated and dried, add auxiliary material or it is complementary into Point, mix, it is encapsulated, to obtain the final product；The water-bindered pill：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add excipient, water pill is dry, to obtain the final product；Honeyed bolus：Weigh bulk pharmaceutical chemicals, beat powder, sieve, add honey, pill is dry, to obtain the final product；Dripping pill：Bulk pharmaceutical chemicals are weighed, adds water or organic solvent to extract, filters, matrix is added in filtrate, mix heating and melting, instill Condensed in not miscible condensate liquid, to obtain the final product.
- 10. purposes of claim 1~6 any one of them pharmaceutical composition in treatment bone split or fracture medicine is prepared.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711331229.3A CN108014236A (en) | 2017-12-13 | 2017-12-13 | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711331229.3A CN108014236A (en) | 2017-12-13 | 2017-12-13 | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108014236A true CN108014236A (en) | 2018-05-11 |
Family
ID=62073442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711331229.3A Pending CN108014236A (en) | 2017-12-13 | 2017-12-13 | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108014236A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949448A (en) * | 2011-08-25 | 2013-03-06 | 左新民 | Dipsacus asperoides powder capsule |
-
2017
- 2017-12-13 CN CN201711331229.3A patent/CN108014236A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102949448A (en) * | 2011-08-25 | 2013-03-06 | 左新民 | Dipsacus asperoides powder capsule |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100431593C (en) | Chinese medicinal formulation for treating hydrocephalus | |
| CN104758844A (en) | Traditional Chinese medicine for treating premature ovarian failure | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN108014237A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN105535495A (en) | Chinese medicinal composition for treating esophageal cancer by reinforcing vital essence and strengthening primordial qi and preparation method | |
| CN103071076B (en) | Traditional Chinese medicament composition for promoting recovery after cesarean section by lavipeditum nursing and application | |
| CN107468857A (en) | A kind of Chinese medicinal preparation method that can treat gastric ulcer | |
| CN108014236A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN108126077A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN107998252A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN108159236A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN108042678A (en) | A kind of pharmaceutical composition for treating bone split or fracture and its preparation method and application | |
| CN105213758A (en) | A kind of Chinese medicine composition for the treatment of chronic pneumonia and preparation method thereof | |
| CN107913374A (en) | A kind of pharmaceutical composition for treating calculus and preparation method thereof | |
| CN108014238A (en) | It is a kind of to treat fracture, pharmaceutical composition of bone split and preparation method thereof | |
| CN108186854A (en) | It is a kind of to treat fracture, pharmaceutical composition of bone split and preparation method thereof | |
| CN107929354A (en) | A kind of pharmaceutical composition for treating calculus and its preparation method and application | |
| CN108785559A (en) | A kind of drug and preparation method thereof for treating respiratory tract infection | |
| CN108992549A (en) | A kind of pharmaceutical composition and preparation method thereof, application | |
| CN108126076A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN108042679A (en) | A kind of pharmaceutical composition for treating fracture or bone split and its preparation method and application | |
| CN108014235A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN107998253A (en) | It is a kind of to treat fracture or the pharmaceutical composition of bone split and its preparation method and application | |
| CN105535658A (en) | Traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
| CN105687499A (en) | Betaxolol containing pharmaceutical composition for treating hypertension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180511 |
|
| WD01 | Invention patent application deemed withdrawn after publication |